At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 29 enrolled
Drug / intervention
Eribulin +1 moredrug
Likely dose
Eribulin 1.4 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Eribulin and Lenvatinib in Advanced Solid Tumors (CTMS# 15-2139)
In Brief
A Phase 2 clinical trial evaluating Eribulin and Lenvatinib for Cancer and Solid Tumor. Completed, enrolled 29 participants across 1 site.
Detailed Summary
The overall purpose of this study is to determine the overall response rate, efficacy and safety of the combination of eribulin and Lenvatinib.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer, Solid Tumor
CountriesUnited States
CollaboratorsEisai Inc.
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 2015
Enrollment StartMay 2016
Primary CompletionNov 2020
Study CompletionJan 2023
TodayJul 2026
First PostedDec 29, 2015
Enrollment StartMay 1, 2016
Primary CompletionNov 24, 2020
Study CompletionJan 12, 2023
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 10.5 years ago
Interventions
Eribulindrug
Will be given by I.V. at 1.4 mg/m2 on day 1 and day 8.
Lenvatinibdrug
Will be taken orally at 20-24 mg daily in each 21 day cycle.